154 related articles for article (PubMed ID: 38745748)
1. Functional remodeling of intraperitoneal macrophages by oncolytic adenovirus restores anti-tumor immunity for peritoneal metastasis of gastric cancer.
Tabuchi M; Kikuchi S; Tazawa H; Okura T; Ogawa T; Mitsui E; Une Y; Kuroda S; Sato H; Noma K; Kagawa S; Ohara T; Ohtsuka J; Ohki R; Urata Y; Fujiwara T
Mol Ther Oncol; 2024 Jun; 32(2):200806. PubMed ID: 38745748
[TBL] [Abstract][Full Text] [Related]
2. Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.
Kanaya N; Kuroda S; Kakiuchi Y; Kumon K; Tsumura T; Hashimoto M; Morihiro T; Kubota T; Aoyama K; Kikuchi S; Nishizaki M; Kagawa S; Tazawa H; Mizuguchi H; Urata Y; Fujiwara T
Mol Ther; 2020 Mar; 28(3):794-804. PubMed ID: 31991110
[TBL] [Abstract][Full Text] [Related]
3. Intraperitoneal Administration of p53-armed Oncolytic Adenovirus Inhibits Peritoneal Metastasis of Diffuse-type Gastric Cancer Cells.
Hori N; Tazawa H; Li Y; Okura T; Kikuchi S; Kuroda S; Ohara T; Noma K; Nishizaki M; Urata Y; Kagawa S; Fujiwara T
Anticancer Res; 2023 Nov; 43(11):4809-4821. PubMed ID: 37909979
[TBL] [Abstract][Full Text] [Related]
4. Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma.
Mochizuki Y; Tazawa H; Demiya K; Kure M; Kondo H; Komatsubara T; Sugiu K; Hasei J; Yoshida A; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Cancer Immunol Immunother; 2021 May; 70(5):1405-1417. PubMed ID: 33151368
[TBL] [Abstract][Full Text] [Related]
5. Modulation of
Ogawa T; Kikuchi S; Tabuchi M; Mitsui E; Une Y; Tazawa H; Kuroda S; Noma K; Ohara T; Kagawa S; Urata Y; Fujiwara T
Mol Ther Oncolytics; 2022 Jun; 25():249-261. PubMed ID: 35615263
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic virus-mediated p53 overexpression promotes immunogenic cell death and efficacy of PD-1 blockade in pancreatic cancer.
Araki H; Tazawa H; Kanaya N; Kajiwara Y; Yamada M; Hashimoto M; Kikuchi S; Kuroda S; Yoshida R; Umeda Y; Urata Y; Kagawa S; Fujiwara T
Mol Ther Oncolytics; 2022 Dec; 27():3-13. PubMed ID: 36212775
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination.
Takakura M; Nakamura M; Kyo S; Hashimoto M; Mori N; Ikoma T; Mizumoto Y; Fujiwara T; Urata Y; Inoue M
Cancer Gene Ther; 2010 Jan; 17(1):11-9. PubMed ID: 19662088
[TBL] [Abstract][Full Text] [Related]
8. Effect of Systemic or Intraperitoneal Administration of Anti-PD-1 Antibody for Peritoneal Metastases from Gastric Cancer.
Kumagai Y; Futoh Y; Miyato H; Ohzawa H; Yamaguchi H; Saito S; Kurashina K; Hosoya Y; Lefor AK; Sata N; Kitayama J
In Vivo; 2022; 36(3):1126-1135. PubMed ID: 35478147
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer.
Lee YS; Lee WS; Kim CW; Lee SJ; Yang H; Kong SJ; Ning J; Yang KM; Kang B; Kim WR; Chon HJ; Kim C
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33199510
[TBL] [Abstract][Full Text] [Related]
10. Boosting Replication and Penetration of Oncolytic Adenovirus by Paclitaxel Eradicate Peritoneal Metastasis of Gastric Cancer.
Ishikawa W; Kikuchi S; Ogawa T; Tabuchi M; Tazawa H; Kuroda S; Noma K; Nishizaki M; Kagawa S; Urata Y; Fujiwara T
Mol Ther Oncolytics; 2020 Sep; 18():262-271. PubMed ID: 32728614
[TBL] [Abstract][Full Text] [Related]
11. Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus.
Hashimoto M; Kuroda S; Kanaya N; Kadowaki D; Yoshida Y; Sakamoto M; Hamada Y; Sugimoto R; Yagi C; Ohtani T; Kumon K; Kakiuchi Y; Yasui K; Kikuchi S; Yoshida R; Tazawa H; Kagawa S; Yagi T; Urata Y; Fujiwara T
Br J Cancer; 2024 Apr; 130(7):1187-1195. PubMed ID: 38316993
[TBL] [Abstract][Full Text] [Related]
12. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
[TBL] [Abstract][Full Text] [Related]
13. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
14. Intraperitoneal cancer-immune microenvironment promotes peritoneal dissemination of gastric cancer.
Sakamoto S; Kagawa S; Kuwada K; Ito A; Kajioka H; Kakiuchi Y; Watanabe M; Kagawa T; Yoshida R; Kikuchi S; Kuroda S; Tazawa H; Fujiwara T
Oncoimmunology; 2019; 8(12):e1671760. PubMed ID: 31741772
[TBL] [Abstract][Full Text] [Related]
15. Macrophages reprogramming improves immunotherapy of IL-33 in peritoneal metastasis of gastric cancer.
Che K; Luo Y; Song X; Yang Z; Wang H; Shi T; Wang Y; Wang X; Wu H; Yu L; Liu B; Wei J
EMBO Mol Med; 2024 Feb; 16(2):251-266. PubMed ID: 38238529
[TBL] [Abstract][Full Text] [Related]
16. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
[TBL] [Abstract][Full Text] [Related]
17. Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells.
Hasei J; Sasaki T; Tazawa H; Osaki S; Yamakawa Y; Kunisada T; Yoshida A; Hashimoto Y; Onishi T; Uno F; Kagawa S; Urata Y; Ozaki T; Fujiwara T
Mol Cancer Ther; 2013 Mar; 12(3):314-25. PubMed ID: 23315976
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer.
Kajiwara Y; Tazawa H; Yamada M; Kanaya N; Fushimi T; Kikuchi S; Kuroda S; Ohara T; Noma K; Yoshida R; Umeda Y; Urata Y; Kagawa S; Fujiwara T
Cancer Immunol Immunother; 2023 May; 72(5):1285-1300. PubMed ID: 36436021
[TBL] [Abstract][Full Text] [Related]
19. Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma.
Kiyokawa J; Kawamura Y; Ghouse SM; Acar S; Barçın E; Martínez-Quintanilla J; Martuza RL; Alemany R; Rabkin SD; Shah K; Wakimoto H
Clin Cancer Res; 2021 Feb; 27(3):889-902. PubMed ID: 33257429
[TBL] [Abstract][Full Text] [Related]
20. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
